Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.

Croxtall JD, Perry CM.

Drugs. 2010 Oct 1;70(14):1885-915. doi: 10.2165/11204950-000000000-00000. Review.

PMID:
20836579
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Oldfield V, Plosker GL.

Drugs. 2006;66(9):1275-99. Review.

PMID:
16827606
4.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
5.

Lopinavir/ritonavir: appraisal of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2007 Apr;43(4):221-47. Review.

PMID:
17460785
6.

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group..

HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x.

7.

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

Barragan P, Podzamczer D.

Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. doi: 10.1517/14656566.9.13.2363 . Review.

PMID:
18710360
8.

Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.

Kaplan SS, Hicks CB.

Expert Opin Pharmacother. 2005 Aug;6(9):1573-85. Review.

PMID:
16086645
9.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team..

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

PMID:
18722869
10.

Lopinavir.

Hurst M, Faulds D.

Drugs. 2000 Dec;60(6):1371-9; discussion 1380-1.

PMID:
11152017
11.
12.

Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C.

HIV Clin Trials. 2009 Mar-Apr;10(2):76-87. doi: 10.1310/hct1002-76.

PMID:
19487177
13.
14.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group..

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.

PMID:
20981785
15.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

PMID:
19487905
16.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
17.
18.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group..

Lancet. 2007 Jul 7;370(9581):49-58.

PMID:
17617272
19.

Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.

Walmsley SL, Cotte L, Rusconi S, Ward DJ, Hicks CB, Meier U, Valdez H, Boucher CA.

AIDS. 2007 Oct 18;21(16):2245-8.

PMID:
18090054
20.

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.

Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D.

Antivir Ther. 2014;19(6):569-77. doi: 10.3851/IMP2736.

PMID:
24458091
Items per page

Supplemental Content

Support Center